Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2012 - 2026)

Sarepta Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 96.53% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 96.53% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 96.77% from the prior year.
• Other Non-Current Liabilities advanced to $1.6 million in Q1 2026 per SRPT's latest filing, from $1.5 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $48.2 million in Q1 2024 and bottomed at $1.5 million in Q4 2025.
• The 5-year median for Other Non-Current Liabilities is $36.9 million (2022), against an average of $33.6 million.
• Across the five-year window, Other Non-Current Liabilities soared 235.45% in 2023 and plunged 96.77% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $36.9 million in 2022, then climbed by 3.25% to $38.1 million in 2023, then advanced by 24.41% to $47.4 million in 2024, then plunged by 96.77% to $1.5 million in 2025, then climbed by 7.72% to $1.6 million in 2026.
• Per Business Quant, the three latest SRPT Other Non-Current Liabilities figures stand at $1.6 million (Q1 2026), $1.5 million (Q4 2025), and $36.3 million (Q3 2025).